Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00046358
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2002-09-26
Brief Title:
The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid a Protein Associated With Alzheimers Disease
Sponsor:
National Institute of Mental Health NIMH
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-Amyloid
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheimers Disease AD
Detailed Description:
There is increasing evidence that nonsteroidal and cholesterol lowering medications may be associated with a delay in the onset of Alzheimers disease AD There is separate evidence that beta-amyloid1-42 is involved in the pathophysiology of AD and levels of beta-amyloid1-42 in the cerebrospinal fluid CSF of AD patients are significantly lower than that found in controls It has been suggested that these standard medications may have indirect effects that alter the normal course of AD but there is no data to directly support this contention in humans Based on previous work it is our hypothesis that CSF beta-amyloid1-42 levels may serve as an early biomarker of AD Any pharmacological induced change in CSF beta-amyloid1-42 might have profound implications for the eventual onset of illness Therefore the purpose of this study is to evaluate the short-term effects of two commonly prescribed nonsteroidal and cholesterol lowering medications ibuprofen and lovastatin on the levels of cerebrospinal fluid beta-amyloid1-42 in a group of normal controls at risk for developing AD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 02-M-0305 | None | None | None |